NasdaqCM - Delayed Quote USD

Genprex, Inc. (GNPX)

2.0700 -0.0300 (-1.43%)

At close: November 6 at 4:00:01 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress

PR Newswire 2d ago

GNPX
-0.95%
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer

PR Newswire 3d ago

GNPX
-0.95%
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

PR Newswire 10d ago

GNPX
-0.95%
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

PR Newswire 17d ago

GNPX
-0.95%
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PR Newswire 1mo ago

GNPX
-0.95%
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

PR Newswire 2mo ago

GNPX
-0.95%
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

PR Newswire 2mo ago

GNPX
-0.95%
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

PR Newswire 3mo ago

GNPX
-0.95%
Genprex to Participate at BIO International Convention 2026

PR Newswire 4mo ago

GNPX
-0.95%
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

PR Newswire 5mo ago

GNPX
-0.95%
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

PR Newswire 6mo ago

GNPX
-0.95%
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

PR Newswire 6mo ago

GNPX
-0.95%

Performance Overview

Return	GNPX	S&P 500 (^GSPC)
YTD	-94.62%	+7.76%
1-Year	-97.99%	+9.77%
3-Year	-99.99%	+68.96%

U.S. markets closed

Genprex, Inc. (GNPX)

Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress

Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex to Participate at BIO International Convention 2026

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting